Metsera, Inc. presents four studies on GLP-1 receptor agonist MET-097i at the ADA conference, showcasing clinical and preclinical data. Metsera, Inc., a biopharmaceutical company focused on obesity ...
Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (MTSR), today announced positive topline data from the Phase 1 clinical ...
Metsera, Inc. (NASDAQ:MTSR) on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results